EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

Aberrant expression of CDK9/cyclin T1 has been found in diffuse large B-cell lymphoma (DLBCL), and suggests that CDK9 is a potential therapeutic target for DLBCL. Here, we firstly demonstrated that CDKI-73, a novel cyclin-dependent kinases (CDK) inhibitor, potently blocks CDK9, triggered apoptosis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Shao, Wei, Fan, Sun, Yi-ming, Gao, Ying-lei, Pan, Lu-lu, Tan, Min-jia, Wang, Shu-dong, Ding, Jian, Chen, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109751/
https://www.ncbi.nlm.nih.gov/pubmed/31289198
http://dx.doi.org/10.3324/haematol.2019.222935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109751/
https://www.ncbi.nlm.nih.gov/pubmed/31289198
http://dx.doi.org/10.3324/haematol.2019.222935

Ejemplares similares